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organomegaly. Because the mass was quite painful and a source of
discomfort to the patient, we decided to remove it immediately and
without further work-up.
In surgical exploration of the thigh, the saphenous vein from
the saphenofemoral junction to the upper third of the leg was sur-
rounded and infiltrated by whitish, rubbery tissue all along its
course. The vessel was removed through a longitudinal incision
from the groin to the upper medial third of the leg. The excision
of the tumor was not challenging, and local exeresis was per-
formed on grossly free margins. In particular, the common
femoral vein at its junction with the great saphenous vein was free
of tumor, and no enlarged lymph nodes were detected upon pal-
pation. The gross specimen consisted of a saphenous vein that was
surrounded and infiltrated by a whitish to brownish, rubbery tis-
sue all along its course (Fig 2, upper panel).
Histologically a large vascular structure was seen (Fig 2, lower
panel), which was diffusely infiltrated by a lymphoid proliferation
sometimes admixed with histiocytes (Fig 3). The lymphoid cells
were large and immunohistochemically stained by monoclonal
antibodies (MoAbs) anti-CD10 and anti-BCL2. C-Myc was also
positive, whereas the neoplastic cells were CD3-negative and
CD79A-negative. Antiactin MoAbs highlighted the venous vas-
cular wall infiltrated by tumor cells. The findings were consistent
with a high-grade, diffuse, large-cell lymphoma of peripheral B
lymphocyte origin, primarily arising in the saphenous vein.
The postoperative course was uneventful. Polichemotherapy
was administered for six cycles (cyclophosphamide, vincristine,
and prednisolone every 28 days). Follow-up CT after
polichemotherapy did not show recurrence or lymph node
enlargement. The patient is now alive and free of tumor 10
months after the operation.
DISCUSSION
This is, to our knowledge, the second case of primary
malignant lymphoma of a vein. The first one was pub-
lished in 1998 by Nomori et al,4 who described a case of
superior vena cava localization.
In any case, malignant tumors arising from venous
walls of the lower extremity are uncommon. Histologically
they are divided into two groups—hemangioendothe-
liomas of intermediate malignancy and leiomyosarcomas.5
To these groups we should add primary malignant lym-
Primary tumors arising from the vessel wall are rare,
and, although primary cardiac malignant lymphoma has
been reported,1-3 a malignant lymphoma originating from
a vein is exceptional. A case of primary malignant lym-
phoma of the superior vena cava has been described in
1998.4 Herein we report a malignant lymphoma primarily
localized within the wall of the internal saphenous vein,
which is, to the best of our knowledge, the first presented
in the medical literature.
CASE REPORT
A 72-year–old white man was admitted to the Department of
Surgery of the University of Rome “Tor Vergata” (Columbus
Hospital) on June 5, 2000. He complained of progressive pain of
the left upper thigh in the crural area. He had no history of
immunosuppression or methotrexate treatment of rheumatoid
arthritis. Furthermore, human immunodeficiency virus and
Epstein-Barr virus exposures were excluded.
Physical examination showed a medial thigh mass and a mod-
erate swelling of the ipsilateral leg. Routine laboratory tests
revealed highly increased serum lactate-dehydrogenase (609 IU/L;
normal, <460 IU/L) and fibrinogen (723 mg/dL; normal, 200-
400 mg/dL) levels. Local thigh ultrasound scanning and com-
puted tomography (CT) showed a dishomogeneous mass of 4.5
cm in diameter, with particular echogenicity and density (Fig 1, A,
B, C) without invasion of adjacent femoral vessels. The mass was
extraluminal at all CT levels examined and showed indistinct mar-
gin and no cleavage planes between the tumor and the great saphe-
nous vein. The color Doppler scan revealed a normal flow in the
femoral vessels but no flow in the internal saphenous vein (Fig 1,
D). CT total body did not reveal lymphadenopathy or
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We herein present a case of primary malignant lymphoma of the saphenous vein. A 72-year-old man suffered from
tumor and pain of the anteromedial aspect of the left upper thigh. Local thigh ultrasound scanning and computed
tomography revealed a mass within the superior third of the internal saphenous vein. The patient underwent surgical
exploration and removal of the saphenous vein between the groin and the upper third of the leg. The resected vessel
was surrounded and infiltrated by a whitish, rubbery tissue all along its course. The histologic findings were consis-
tent with high-grade, diffuse, large-cell lymphoma of peripheral B lymphocyte origin, primarily arising in the saphe-
nous vein. Antiactin monoclonal antibodies depicted the venous vascular wall infiltrated by tumor cells, confirming the
lymphomatous localization within the saphenous vein. The patient is now alive and free of tumor 10 months after the
operation. (J Vasc Surg 2002;35:168-71.)
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phoma, considering the case we observed. Patients with
scleroderma have been reported to show an increased inci-
dence of lung, breast, hematopoietic, and lymphoprolifer-
ative malignancies6; in most patients, scleroderma occurs
first and is followed by development of a lymphoma.
Scleroderma developed in the patient with primary malig-
nant lymphoma of the superior vena cava4 41 months after
the operation. No scleroderma has yet developed in our
patient.
As is well known, extranodal non-Hodgkin’s lym-
phoma usually develops in organs containing recognizable
areas of lymphoid tissue such as tonsils, stomach, small
bowel, and skin. Some recent studies have pointed to the
concept of mucosa-associated lymphoid tissue to explain
the occurrence of lymphomas in certain extranodal tis-
sues,7,8 and primary tumors in unusual locations that do
not contain lymph nodes or easily apparent lymphoid
aggregates, such as the breast, have been reported.9
Regarding the spread modalities of the neoplasms that
eventually enter in the differential diagnosis with primary
venous lymphoma, in a series of 13 primary venous
leiomyosarcomas, metastases developed in five patients.10
In another condition, intravascular lymphomatosis (ILV),
metastatic diffusion seems to be more common because
most of the reported patients showed widespread disease
and involvement of the central nervous system.11
In the case we have described, no lymph node struc-
tures involved by the lymphoma were found, either in the
inguinal region or in the leg compartments adjacent the
saphenous vein, thus confirming that the site of origin is to
Fig 1. Primary malignant lymphoma of the saphenous vein. A, The ultrasound scan shows solid, hypoechoic palpable mass with a cen-
tral hyperechoic area. B, Medial to the mass is a neoplastic tissue with a peculiar cerebroid appearance involving soft tissues. C, Local
CT showed dishomogeneous mass (arrow) with peripheral enhancement, without invasion of femoral vessels. D, Color Doppler scan
showed a normal flow in the femoral vessels.
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be identified in the vessel wall. Our staging preoperative
work-up included only a CT scan because the lymphoma-
tous nature of the disease was not suspected before surgery
and biopsies were not carried out. One might object that
our case could represent a primary soft tissue lymphoma
arising in the periadventitial tissues that, for unknown rea-
sons, has invaded the saphenous vein wall and extended all
along its course. Even if we cannot rule out this possibility,
we believe that if this were indeed true, it would not
change the uniqueness of such clinical presentation consid-
ering that no primary soft tissue lymphomas with such
exceptional features have to date been reported. In fact,
primary soft tissue lymphomas, even if rare, can occur in
the soft tissues of the extremity, but as a mass without the
localization and spread observed in our case.12 In any
Fig 2. Primary malignant lymphoma of the saphenous vein.
Upper panel, Saphenous vein appears surrounded and infiltrated
by a whitish to brownish, neoplastic tissue that extends all along
its course. Lower panel, The wall of the vein is infiltrated and
replaced by a monomorphous large lymphoid cell proliferation
that invades up to the intimal layers. At the top of the field the
vascular lumen is seen (hematoxyline-eosine × 250).
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Fig 3. Primary malignant lymphoma of the saphenous vein.
Upper panel, Low-power view of the lymphoid infiltrate (arrows)
at a different level along the course of the saphenous vein shows
a mainly periadvential location in close connection with the
venous muscular wall (hematoxyline-eosine × 100). Lower panel,
High-power view of the lymphoma shows a uniform prolifera-
tion of large cells with prominent nuclei and nucleoli consistent
with the diagnosis of high-grade large cell lymphoma (Giemsa
stain × 400).
event, antiactin MoAbs highlighted the venous vascular
wall infiltrated by tumor cells, thus confirming the lym-
phomatous localization within the saphenous vein.
In such a rare case, surgical treatment in terms of
extent of excision and tumor-free margins should include
wide local resection of the mass. In summary, we can say
that the treatment of the presented case did not differ
from that of other anatomical-site primary lymphoma.
In fact, this kind of management, together with mul-
tidrug chemotherapy, is the recommended treatment.12
Gallium-67 imaging has been advocated to define residual
disease and predict outcome,13 but we did not perform it
because this diagnostic tool is not routinely used at our
institution. It is important to remark that 10% elevation in
the serum lactate-dehydrogenase, age >60 years, and
bulky disease are independent prognostic factors for over-
all survival in patients treated for aggressive lymphoma.14
In general, the most important clinical differential
diagnosis should then be made with primary venous
leiomyosarcoma, a rare but lethal disease that can arise in
a large vein, including the great saphenous vein,6 and that
is present as a tumor mass. In these cases, surgical treat-
ment should include wide local excision with free margins
and eventually postoperative adjuvant therapy. Because of
the possibility of invasion of adjacent organs, surgery may
be technically challenging and may be responsible for peri-
operative morbidity and mortality.6
In conclusion, it seems important to remark that pri-
mary lymphoma of a large vein is a pathologic condition
involving the layers of the wall and, eventually, the periad-
ventitial tissues and must not be confused with ILV, a rare
malignancy characterized by neoplastic proliferation of
lymphoid cells within the lumens of arteries, small veins,
and capillaries.15 Although ILV should be suspected in
adult patients with unclear meningoencephalitic syn-
drome, confusional state, dementia, or other unexplained
neurologic conditions with signs of a systemic disease,16
vein lymphoma, based on the two cases in the world liter-
ature (including our case), is to be considered in the case
of a soft tissue mass localized within the wall and periad-
ventitial tissues of a major venous vessel.
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